Answer
Jakavi (ruxolitinib phosphate) is contraindicated in patients with hypersensitivity to the active substance or any excipient listed in section 6.1.
Sources for this answer
- Jakavi 5mg, 10mg, 15mg and 20mg TabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.3 Contraindications · Version 29Document updated
Sources checked